The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Management of early stage lung cancer with TKIs
Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the importance of developing treatment strategies for earlier stages of lung cancer. Osimertinib has found to be efficacious in EGFR-mutant lung cancer previously treated with chemoradiation and the ALINA trial (NCT03456076) demonstrated that patients with resected ALK-positive non-small cell lung cancer (NSCLC) responded well to alectinib. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
